NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

Study May Proceed letter received from FDAPotential to initiate registrational study in 2024RADNOR, Pa., Dec. 18, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. , a clinical-stage...

Related Keywords

United States ,France ,Americans ,French ,Michael Manyak ,Prnewswire Nrx Pharmaceuticals Inc ,World Health Organization ,Alvogen Pharmaceuticals ,Nrx Pharmaceuticals ,Source Nrx Pharmaceuticals Inc ,Us National Institutes Of Health ,Global Medical Affairs ,George Washington University ,Glaxosmithkline ,Nasdaq ,Company Quarterly Reports On Form ,Nrxp Nrx Pharmaceuticals ,Exchange Commission ,Investigational New Drug Application ,Urinary Tract ,Urinary Tract Infections ,Chief Scientist ,World Health ,Hope Therapeutics ,Lead Clinical Advisor ,Global Medical Affairs Director ,Chief Medical Advisor ,Crisis Response ,Adjunct Professor ,Tropical Medicine ,Baylor College ,Medicine National School ,Qualified Infectious Disease Product ,Breakthrough Therapy ,New Drug Application ,Fast Track Designation ,Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Markets ,